AbbVie registers Phase 1 trial comparing upadacitinib, tofacitinib, baricitinib in healthy adultsSep 30Weekly roundup, 4 itemsABBV-722AbbVie
Merck registers two new Phase 1/2 trials; KEYVIBE-005 results remain on recordSep 30Weekly roundup, 4 itemsMerck & Co., Inc.pembrolizumabUpdated
Exelixis registers Phase 2 trial pairing zanzalintinib with pembrolizumab in NSCLCSep 29Trial updateExelixispembrolizumab
Sanofi's SAR444881 tumor trial results posted after early stop; hemophilia study recruitsSep 29Weekly roundup, 2 itemsSanofi
PDS Biotech publishes VERSATILE-002 Phase 2 results for PDS0101 in JAMA OncologySep 22Clinical readoutPDS Biotechnology Corp
Summit reports updated HARMONi overall survival data at WCLC 2026Sep 15Clinical readoutivonescimabSummit Therapeutics
Summit Therapeutics registers Phase 2/3 HARMONi-GU1 trial in urothelial carcinomaSep 11Trial updateivonescimabSummit Therapeutics
Pyxis Oncology reports updated Phase 1 data for MICVO in head and neck cancerSep 9Clinical readoutPyxis Oncology, Inc
Inhibrx reports Phase 2 HNSCC data showing INBRX-106 combo nearly doubles response rateSep 8Clinical readoutInhibrx Biosciences, Inc
Bicara Therapeutics updates registry record NCT07807163: recruitingSep 8Trial updateBicara Therapeuticsficerafusp alfaRecord notice
Sutro Biopharma registers Phase 1 first-in-human trial of ADC STRO-006 in solid tumorsSep 8Trial updateSTRO-006Sutro Biopharma, Inc.
Novartis-linked melanoma trial posts results; new ITP preference survey and LASIK study activeAug 27Weekly roundup, 4 itemsdabrafenibitraconazole
Revolution Medicines registers Phase 3 zoldonrasib trial for RAS G12D-mutated NSCLCAug 20Trial updateRevolution Medicines, Inc.zoldonrasib
Lilly registers Phase 3 depression trial; posts results for two psoriasis and oncology studiesAug 20Weekly roundup, 5 itemsabemaciclibbrenipatide
AstraZeneca halts eVOLVE-Lung02 trial of volrustomig in lung cancerAug 17Clinical readoutAstraZenecavolrustomig
Citius Pharmaceuticals reports fiscal Q3 2026 results as LYMPHIR launch continuesAug 14Quarterly updateCitius Pharmaceuticals, Inc.denileukin diftitox-cxdl
BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 resultsAug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.
TuHURA reports Q2 2026 results, outlines second-half milestones for AML and MCC programsAug 14Quarterly updateKintara Therapeutics, Inc.
Citius Oncology reports LYMPHIR order growth in fiscal Q3 2026, expands sales forceAug 14Quarterly updateCitius Oncology, Inc.Citius Pharmaceuticals, Inc.
Pyxis Oncology reaffirms MICVO data timelines, closes $50 million private placementAug 13Quarterly updatePyxis Oncology, Inc
AbbVie posts Crohn's OLE results; registers Phase 3 lung cancer and Phase 1 glabellar lines trialsAug 13Weekly roundup, 3 itemsABBV-1480AbbVie
Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trialAug 13Quarterly updateCandel Therapeutics, Inc.
NextCure's NC410-pembrolizumab trial ends after Phase 1b; Part 2 never launchedAug 13Trial updateMerck & Co., Inc.NC410
Eikon Therapeutics reports Q2 2026 results with seven ESMO abstracts and melanoma trial progressAug 13Quarterly updateEikon Therapeutics
Inhibrx reports Q2 2026 results, sets Q3 PFS readout for INBRX-106Aug 13Quarterly updateInhibrx Biosciences, Inc
Adagene reports mid-2026 results, muzastotug data across CRC and HCC trialsAug 12Clinical readoutAdagene Inc
Bicara names successor CEO, reports pivotal trial on track for 2027 readoutAug 11Quarterly updateBicara Therapeutics
Genmab terminates Phase 1/2 GEN1055 trial for strategic reasons; results now postedAug 11Trial updateBioNTech SEGEN1055
BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trialsAug 11Quarterly updateBridgeBio Oncology Therapeutics, Inc.
Pliant reports Q2 2026 results, adds two oncology-focused directors as FORTIFY enrollment continuesAug 11Quarterly updatePliant Therapeutics, Inc.PLN-101095
Actuate-linked trial of 9-ING-41 plus carboplatin in salivary gland cancer posts resultsAug 7Trial updateActuate Therapeutics Inc.pemetrexed
AbbVie registers three new trials spanning obesity, head and neck cancer, and atopic dermatitisAug 7Weekly roundup, 3 itemsABBV-295AbbVie
CytomX reports Q2 2026 results, advances Varseta-M toward first registrational studyAug 6Quarterly updateCytomX Therapeutics
Iovance posts record Q2 2026 revenue, gains FDA fast track for lifileucel in sarcomasAug 6Quarterly updateIovance Biotherapeutics, Inc.lifileucel
Generate Biomedicines reports Q2 2026 results, advances asthma and oncology pipelineAug 6Quarterly updateGenerate Biomedicines
Foghorn reports Q2 2026 results, FHD-909 trial on track with LillyAug 6Quarterly updateEli LillyFoghorn Therapeutics Inc.
Immunocore posts Q2 KIMMTRAK sales growth as key melanoma trial nears enrollment targetAug 6Quarterly updateImmunocore Ltdtebentafusp
Exelixis registers Phase 3 STELLAR-316 trial of zanzalintinib in colorectal cancer MRDAug 6Trial updateExelixisMerck & Co., Inc.
Corbus reports Q2 2026 results, clears FDA hurdle for CRB-701 trialAug 6Quarterly updateCorbus Pharmaceuticals Holdings, Inc.
Arvinas registers first-in-human Phase 1/2 trial of ARV-6723 in advanced solid tumorsAug 6Trial updateARV-6723Arvinas Inc.
Summit Therapeutics starts Phase II/III bladder cancer trial for ivonescimabAug 5Clinical readoutivonescimabSummit Therapeutics
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination dataAug 5Quarterly updatedaraxonrasibRevolution Medicines, Inc.
Merck posts Q2 loss on Terns charge, raises full-year sales outlookAug 4Quarterly updateMerck & Co., Inc.
Precigen posts first quarterly profit as PAPZIMEOS revenue more than doublesAug 4Quarterly updatePrecigen, Inc
Gilead reports Q2 2026 results with three FDA approvals, three positive Phase 3 readoutsAug 4Quarterly updateGilead Sciences
Krystal Biotech posts second-quarter results, outlines multiple late-2026 pipeline readoutsAug 3Quarterly updateKrystal Biotech, Inc.
Iovance's cervical cancer TIL trial C-145-04 terminated after meeting event thresholdJul 31Trial updateIovance Biotherapeutics, Inc.lifileucel
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
GeoVax reaffirms Q4 start for GEO-MVA pivotal trial, reports $3.1 million cashJul 27Quarterly updateGeoVax Labs, Inc.
NuCana's NuTide:303 trial for NUC-3373 combos terminated; results posted with 19 enrolledJul 23Trial updatefosifloxuridine nafalbenamideNuCana plc
Anixa Biosciences-linked TNBC vaccine trial posts completed results after five-year runJul 17Trial updateAnixa Biosciences Inc
Immutep reports 30.9-month median survival in Phase I NSCLC combination trialJul 13Clinical readoutIMMUTEP Ltd
GSK posts bepirovirsen QT results; registers Mo-Rez ovarian, endometrial Phase 3 trialsJul 10Weekly roundup, 6 itemsbepirovirsencamlipixant
Pyxis Oncology announces up to $114 million private placement for MICVO programJul 2Quarterly updatePyxis Oncology, Inc
Genmab-BioNTech trial of GEN1042 combos posts results after early end for lack of efficacyJul 2Trial updateBioNTech SEGEN1042
Sign inSign in